Dose Ranging Study to Evaluate the Efficacy and Safety of MEDI8852 in Adults who are Hospitalized with Type A Influenza.

Study identifier:D6000C00003

ClinicalTrials.gov identifier:NCT03028909

EudraCT identifier:N/A

CTIS identifier:N/A

Will Be Recruiting

Official Title

A Phase 2b, Randomized, Double-blind, Single-dose, Active-controlled, Dose Ranging Study to Evaluate the Efficacy and Safety of MEDI8852 in Adults who are Hospitalized with Influenza Caused by Type A Strains

Medical condition

Influenza – Type A strains

Phase

Phase 2

Healthy volunteers

Study drug

Oseltamivir, MEDI8852, Placebo

Sex

All

Estimated Enrollment

450

Study type

Interventional

Age

18 Years - 99 Years

Date

Study Start Date: 01 May 2017

Estimated Primary Completion Date: 01 May 2019

Estimated Study Completion Date: 01 May 2019

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Jan 2017 by MedImmune, LLC

Collaborators

Inclusion and exclusion criteria

Inclusion Criteria

Age 18 years or older at the time of screening.
Written informed consent and any locally required authorization (eg, Health Insurance Portability and Accountability Act [HIPAA] in the United States, Data Privacy Directive in Europe) obtained from the subject/legal representative prior to performing any protocol related procedures, including screening evaluations.
Females of childbearing potential who are sexually active with a nonsterilized male partner must have evidence of not being pregnant upon enrollment and have a negative pregnancy test prior to administration of investigational product. Females of childbearing potential are defined as those who are not surgically sterile (ie, bilateral tubal ligation, bilateral oophorectomy, or complete hysterectomy), premenarchal, or postmenopausal (defined as 12 months with no menses without an alternative medical cause). Hospitalized ≤ 72 hours prior to receipt of a positive diagnostic test for influenza A; confirmed with positive rapid antigen test (supplied or approved by the sponsor), or confirmed with culture, polymerase chain reaction, or antigen testing at the study site. Onset of influenza symptoms ≤ 144 hours (≤ 6 days) prior to randomization. Receiving supplemental oxygen. Expected to participate in the study through Day 60.

Exclusion Criteria

-Any condition that, in the opinion of the investigator, would interfere with evaluation of study drugs or interpretation of subject safety or study results.
-Concurrent enrollment in another clinical study involving an investigational treatment. -Hospitalized > 72 hours (> 3 days) prior to receipt of a positive diagnostic test for influenza A.
- Receipt of > 72 hours or > 6 doses of treatment with a neuraminidase (NA) inhibitor. -Receipt of any investigational antiviral medications within 30 days prior to study drug dosing.
-Previous receipt of an influenza mAb within past 100 days.
-Pregnant or nursing female.
-History of allergic disease or reactions likely to be exacerbated by any components of the study drugs (MEDI8852 or oseltamivir).
-Diagnosis of influenza B infection within 14 days prior to randomization.
-Employees of the sponsor, clinical study site, or any other individuals involved with the conduct of the study, or immediate family members of such individuals.

No locations available

Arms	Assigned Interventions
Experimental: Oseltamivir + low dose MEDI8852 Low Dose of MEDI8852 + Oseltamivir will be studied	Drug: Oseltamivir Standard of care for influenza caused by Type A strains Other Name: Tamiflu Drug: MEDI8852 MEDI8852 is a human IgG1 kappa monoclonal antibody (mAb) administered via infusion. Other Name: MEDI8852
Experimental: Oseltamivir + high dose MEDI8852 High dose of MEDI8852 + Oseltamivir will be studied.	Drug: Oseltamivir Standard of care for influenza caused by Type A strains Other Name: Tamiflu Drug: MEDI8852 MEDI8852 is a human IgG1 kappa monoclonal antibody (mAb) administered via infusion. Other Name: MEDI8852
Active Comparator: Oseltamivir + Placebo Oseltamivir in conjunction with placebo will be studied.	Drug: Oseltamivir Standard of care for influenza caused by Type A strains Other Name: Tamiflu Drug: Placebo Salt-water solution containing no active ingredients.

"There is no result for the study"

Documents available

Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Study Information Center

1-877-240-9479

information.center@astrazeneca.com

Sponsors

Collaborators

Inclusion Criteria

Exclusion Criteria

Trial Results Summaries